Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/179215
Title: | Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Withdrawal Is Associated with Higher Mortality in Hospitalized Patients with COVID-19 |
Author: | Roy Vallejo, Emilia Sánchez Purificación, Aquilino Torres Peña, José Sánchez Moreno, Beatriz Arnalich Fernández, Francisco García Blanco, María López Miranda, José Romero Cabrera, Juan Herrero Gil, Carmen Bascunana, José Rubio-Rivas, Manuel Pintos Otero, Sara Martínez Sempere, Verónica Ballano Rodríguez-Solís, Jesús Gil Sánchez, Ricardo Luque del Pino, Jairo González Noya, Amara Navas Alcántara, María Cortés Rodríguez, Begoña Alcalá, José Suárez Lombraña, Ana Andrés Soler, Jorge Gómez Huelgas, Ricardo Casas Rojo, José Millán Núñez-Cortés, Jesús SEMI-COVID-19 Network |
Keywords: | COVID-19 Hospitals Pacients hospitalitzats Pronòstic mèdic COVID-19 Hospitals Hospital patients Prognosis |
Issue Date: | 15-Jun-2021 |
Publisher: | MDPI AG |
Abstract: | Our main aim was to describe the effect on the severity of ACEI (angiotensin-converting enzyme inhibitor) and ARB (angiotensin II receptor blocker) during COVID-19 hospitalization. A retrospective, observational, multicenter study evaluating hospitalized patients with COVID-19 treated with ACEI/ARB. The primary endpoint was the incidence of the composite outcome of prognosis (IMV (invasive mechanical ventilation), NIMV (non-invasive mechanical ventilation), ICU admission (intensive care unit), and/or all-cause mortality). We evaluated both outcomes in patients whose treatment with ACEI/ARB was continued or withdrawn. Between February and June 2020, 11,205 patients were included, mean age 67 years (SD = 16.3) and 43.1% female; 2162 patients received ACEI/ARB treatment. ACEI/ARB treatment showed lower all-cause mortality (p < 0.0001). Hypertensive patients in the ACEI/ARB group had better results in IMV, ICU admission, and the composite outcome of prognosis (p < 0.0001 for all). No differences were found in the incidence of major adverse cardiovascular events. Patients previously treated with ACEI/ARB continuing treatment during hospitalization had a lower incidence of the composite outcome of prognosis than those whose treatment was withdrawn (RR 0.67, 95%CI 0.63-0.76). ARB was associated with better survival than ACEI (HR 0.77, 95%CI 0.62-0.96). ACEI/ARB treatment during COVID-19 hospitalization was associated with protection on mortality. The benefits were greater in hypertensive, those who continued |
Note: | Reproducció del document publicat a: https://doi.org/10.3390/jcm10122642 |
It is part of: | Journal of Clinical Medicine, 2021, vol. 10, num. 12, p. 2642 |
URI: | http://hdl.handle.net/2445/179215 |
Related resource: | https://doi.org/10.3390/jcm10122642 |
ISSN: | 2077-0383 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
jcm-10-02642-v3.pdf | 3.97 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License